Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

Brains Bioceutical opens UK’s largest EU GMP-grade licensed cannabinoid research and commercial production facility, The Canadian Business Journal

VANCOUVER, BC & SANDWICH, UK, September 29, 2022 (GLOBE NEWSWIRE) — Brains Bioceutical Corp (“Brains” or the “Company”) is pleased to announce the opening of its recently completed EU-GMP cannabinoid manufacturing facility. I am happy. Brains Bio announced Thursday, September 29, 2022, the media, investors, researchers, partners and others related to the company’s developing position as a leading supplier in the field of EU GMP cannabinoid-based active pharmaceutical ingredients. Held a grand opening event for stakeholder members.

Brains Bio’s executive team and board of directors welcomed guests and dignitaries from the global pharmaceutical sector, the medical and public health sector, local and national politics, and the business community to celebrate this important achievement.

Brains Chairman and CEO Ricky Brar said: “Having one of the largest EU GMP-grade cannabinoid R&D and commercial facilities positions Brains Bio as the number one supplier of safe, natural cannabinoid APIs, and our team sets the highest and most stringent production standards in the industry. did.”

Recognizing the significant opportunities and gaps in cannabinoid research and data, Brains Bio is committed to developing new treatments for major diseases by partnering with numerous organizations and institutions conducting preclinical research and clinical trials worldwide. Committed to providing evidence supporting the efficacy and safety of cannabinoids. .

Brains Bio’s market-leading position is further enhanced by a regulatory package that includes::

  • An actively maintained EU Active Substances Master File (ASMF).
  • US Drug Master File (DMF) submitted to the US Food and Drug Administration (FDA),
  • Drug Substance (DS) Section of the Investigational Product Dossier (IMPD)
  • German DAC monograph compliant.
  • Pharmaceuticals (DP) section of IMPD available from third-party partners
  • 36 months of stability data.
  • Over 350 commercial batches manufactured with resulting batch consistency and standardization data.
  • Approved IND application to US FDA.
  • Non-GMO, Kosher, Halal
  • Tested Free of THC and Banned Substances by Informed Choice, NSF, INRS (WADA Accredited Lab)
  • NSF certified

BSPG Laboratories, a wholly owned subsidiary of Brains Bio, and subsequent expansion of the facility, will provide the infrastructure to become the world’s leading cannabinoid API maker. Dean Billington, Global Chief Operating Officer of Brains Bio, said: “This expanded facility will eight-fold our capacity to manufacture CBD and other cannabinoids. With the team, infrastructure and partnerships in place, Brains Bio is rapidly expanding into both nutraceuticals and pharmaceutical cannabinoids. We have become an industry leader.”

To date, the current natural EU GMP cannabidiol API manufactured by BSPG has been used in more than 15 clinical trials, demonstrating its efficacy for the treatment of COVID-19, epilepsy, anxiety, insomnia, opioid addiction, and muscle inflammation. We are investigating the effect.

Learn more about Brains Bio here. www.brainsbioceutical.com.

About Brains Bioceutical Corporation

Brains Bioceutical is the leader in evidence-based phytocannabinoid health solutions that enhance lives and treatment options for all. Brains Bio is a leading manufacturer of natural and pure Active Pharmaceutical Ingredients (APIs) with a unique set of licenses and registrations. Brains Bio is strategically positioned to take advantage of a complex regulatory environment and secure first-mover and product quality advantages. Brains Bio is diversified in the pharmaceutical, medical and nutraceutical sectors within the rapidly growing cannabinoid market, offering a strong and unique value proposition.

This news release contains forward-looking statements or information that are forward-looking statements within the meaning of the securities laws (“forward-looking statements”). Often, but not always, forward-looking statements include statements such as “plans,” “anticipates,” “does not expect,” “expects,” “estimates,” “intends,” “anticipates,” ‘, or ‘unexpected’, ‘believe’ or variations of such words or phrases, or that a particular action, event or outcome is ‘could’, ‘could’, ‘could’ states or will be achieved. All statements other than statements of historical fact in this news release are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. Statements containing predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance discussions may be forward-looking statements and not statements of historical fact. Risks, uncertainties and other factors associated with forward-looking statements may cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. may differ. Although we believe that the assumptions and factors used in making the forward-looking statements in this news release are reasonable, actual results and future events may differ materially from those projected. Therefore, there is no guarantee that such statements will prove to be accurate. with such a statement. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this news release and the Company may not reflect new information, subsequent events or otherwise, unless required by the applicable security. does not undertake any obligation to publicly update such forward-looking statements. law.

Media Inquiries:

Calvin Rasode, Vice President of Marketing
Phone: 1-855-927-2476
Email: [email protected]

Contact information for investors:
Email: [email protected]

Website: www.brainsbio.com

CBJ Newsmaker

Brains Bioceutical opens UK’s largest EU GMP-grade licensed cannabinoid research and commercial production facility, The Canadian Business Journal

Source link Brains Bioceutical opens UK’s largest EU GMP-grade licensed cannabinoid research and commercial production facility, The Canadian Business Journal

Related Articles

Back to top button